Please assess the completion status of the following clinical trial:

Trial Title: Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion:~* Histologically or cytologically confirmed advanced adenocarcinoma of the prostate~  - Radiographically proven bone metastasis from prostate cancer~* Androgen refractory disease (including anti-androgen withdrawal)~* Secondary hyperparathyroidism, defined as two parathyroid hormone (PTH) values \> 70 pg/mL, 14 days apart~* ECOG performance status 0-2~* Leukocytes ≥ 3,000/μL~* Absolute neutrophil count ≥ 1,500/μL~* Platelets ≥ 100,000/μL~* Total bilirubin normal~* AST/ALT ≤ 2.5 times upper limit of normal~* Creatinine clearance ≥ 60 mL/min~* Calcium normal~* 25-hydroxyvitamin D (25-OHD) ≥ 20 ng/mL~* 1,25(OH)_2D normal~* Patients with serum 25-OHD indicative of vitamin D insufficiency are eligible provided they are treated with ergocalciferol to raise 25-OHD levels to 20 ng/mL prior to paricalcitol therapy~* More than 8 weeks since prior bisphosphonates~* More than 2 weeks since prior palliative radiotherapy~* More than 4 weeks since other prior therapy~* No more than one prior taxane-containing chemotherapy regimen for metastatic disease~* Multiple lines of prior therapy with hormonal agents allowed~* Concurrent corticosteroids allowed provided the dose remains stable during the study period~Exclusion:~* Underlying metabolic bone disease or vitamin D deficiency~* History of hypercalcemia~* Concurrent uncontrolled illness or co-morbid condition (including psychiatric illness) that would interfere with study compliance~* Concurrent ergocalciferol supplementation~* Concurrent chemotherapy or hormonal therapy~* Concurrent investigational or commercial agents for the malignancy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).